Big Pharma’s retreat from antibiotic drug discovery has potentially contributed to the slump in output. Roche bucked the trend by re-entering the field a few years back, striking a string of deals with biotechs forging ahead in the then-unfashionable sector.
In parallel, perceptions of the potential of the field among the people who perform and fund some early-stage research have started to shift.
“I think there's increasing recognition in the biotech sector and [among] people who invest in biotech companies that innovation in this field is so badly needed from a global medical perspective that it becomes a potentially interesting area in which to invest,” Reid said.
IPIX time will come. They just need to keep the trials rolling and that is exactly what they are doing. Take a look at Sox's stickied post. It should be easy on the eyes to see the progress since 2012. Very promising for shareholders.
Here is another article that relates to IPIX also. It shows the NEED for AI drugs and specifically the indication hidradenitis suppurativa in which IPIX will be testing soon. This article references another drug that is administered via injection. IPIX should be able to demand a large market once approved via oral or topical.
News 
Market Data 
Discover 
AI
